GeoVax Labs, Inc. (Nasdaq: GOVX) today underscored the strategic positioning of its oncology asset, Gedeptin® (Ad/PNP), against the backdrop of increasing industry investment in next-generation in vivo cancer therapies. The clinical-stage biotechnology company emphasized Gedeptin’s potential to enhance the effectiveness of immune checkpoint inhibitors and other emerging oncology modalities, particularly in solid tumors that are immunologically ‘cold.’
Recent high-profile transactions across the biopharmaceutical sector reflect a growing focus on therapies that simplify delivery and expand therapeutic reach. However, a central challenge persists: many tumors fail to elicit a robust immune response, limiting the efficacy of advanced treatments. GeoVax believes Gedeptin is uniquely positioned to address this limitation.
‘While the industry is investing heavily in next-generation cell and gene therapies, the ability to positively modify the local tumor environment is believed to be one of the critical determinants of clinical success,’ said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. ‘Gedeptin is designed to directly destroy both proliferating and non-proliferating tumors, while also demonstrating high bystander activity due to the ability of the in situ generated cytotoxic agent to diffuse into neighboring tumor cells.’
Gedeptin is a gene-directed enzyme prodrug therapy (GDEPT) delivered intratumorally. It works by generating purine nucleoside phosphorylase (PNP), which selectively destroys tumor cells. Preclinical studies have shown that PNP treatment can be additive or synergistic with checkpoint blockade agents. In metastatic tumor models, treatment of a single lesion sensitized tumors to checkpoint inhibitors, presumably by destroying tumor tissue, exposing neoantigens, and enhancing immune response at distant untreated lesions. This dual mechanism—local cytotoxicity combined with immune enhancement—offers a potential improved approach for treating solid tumor metastatic disease.
GeoVax has generated preclinical, clinical, and translational data supporting Gedeptin’s ability to induce localized tumor cell death while minimizing systemic toxicity and potentially improving response rates when combined with immune checkpoint inhibitors. The company is advancing Gedeptin in combination with checkpoint inhibition in a planned Phase 2 clinical trial for first-line head and neck cancer, with additional indications under evaluation.
‘Checkpoint inhibitors have transformed cancer care, but many patients still do not achieve durable responses,’ said Kelly T. McKee, M.D., Chief Medical Officer of GeoVax. ‘We believe Gedeptin is well positioned as a combination-enabling platform designed to enhance therapeutic response across checkpoint inhibitors and other emerging oncology modalities.’
Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers. GeoVax continues to evaluate strategic partnerships and collaborations to advance clinical development and potential commercialization of Gedeptin-based combination therapies. More information about GeoVax and its pipeline is available at www.geovax.com.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is GeoVax Positions Gedeptin as Immune-Sensitizing Platform Amid Rising Investment in In Vivo Cancer Therapies.